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ORIGINAL ARTICLE
INTRODUCTION 
In critically-ill patients who have multi organ 
failure (MOF), liver dysfunction frequently occurs. 
Liver dysfunction is considered less dangerous and 
less threatening than the respiratory, cardiovascular, or 
renal failure, since it has been frequently overlooked.1
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ABSTRACT
Background: In critically-ill patients, liver dysfunction plays a significant role on patient’s morbidity and 
mortality in the intensive care unit (ICU). Metabolic, hemodynamic and inflammatory factors also contribute in 
liver damage. Bilirubin is one of clinical markers for liver dysfunction. Some literatures indicated that patients 
with hyperbilirubinemia have higher mortality rate. The aim of this study was to assess the death prognosis of 
critically-ill patients with hyperbilirubinemia.
Method: This study was an observational, prospective, and cohort study. All patients at the ICU of Kariadi 
hospital with hyperbilirubinemia were consecutively recruited over 8-month period from May 1st 2008 to January 
31st 2009.  Hyperbilirubinemia was defined as serum bilirubin levels ≥ 1.3 mg/dL for at least 72 hours and no 
hyperbilirubinemia was observed when the patients were admitted to the hospital. 
Results: Of 79 subjects who fulfilled inclusion criteria, the incidence of hyperbilirubinemia in critically-
ill patients was 39.2%. About 56 subjects were enrolled in the study. Among them, 28 subjects showed 
hyperbilirubinemia and the other 28 subjects were included in the control group. There was no significant 
difference regarding the baseline characteristics of hyperbilirubinemia group and non-hyperbilirubinemia 
group. At the end of the study, the mortality rate in hyperbilirubinemia patients were 60.7% and 21.3% in the 
non-hyperbilirubinemia patients. The relative risk (RR) of death was 2.8 (95% CI = 1.3 - 6.1; p = 0.003).
Conclusion: The incidence of hyperbilirubinemia was high in critically ill-patients hospitalized in the ICU 
of Kariadi hospital. The incidence of death between non-hyperbilirubinemia and hyperbilirubinemia subjects 
was significantly different. The significant relative risk of death indicates that hyperbilirubinemia may have 
influences on the mortality rate of critically-ill patients hospitalized in the ICU.
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Liver dysfunction in critically-ill patients may occur 
due to shock, impaired liver circulation, decreased 
oxygen supply, and inflammation. Such condition, 
often called shock liver syndrome, explains the state of 
shocked liver in critically-ill patients. Pathophysiology 
of the syndrome may include hemodynamic disorders, 
metabolic, and inflammatory factors.2 Conjugated 
bilirubin levels have not often been examined in 
patients without visible jaundice. However, Brienza 
et al found evidences that patients who had mild 
hyperbilirubinemia (> 2.0 mg/dL) and went to surgery 
had higher mortality rate, as well as in patients with 
sepsis, multiple injuries, totally parenteral nutrition 
and mechanical ventilation supported by positive end 
expiratory pressure.1,3,4,5
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The aim of this study was to assess the effect of 
conjugated hyperbilirubinemia on the prognosis of 
patients who all been treated in the intensive care unit. 
Moreover, the aim was also to assess the death prognosis 
in critically-ill patients with hyperbilirubinemia who 
had all been treated in the intensive care unit (ICU) of 
Kariadi hospital. 
METHOD
In order to assess the prognosis of critically-ill 
patients who had hyperbilirubinemia, we conducted 
an observational study with cohort design. We studied 
dependent and independent variables. The dependent 
variable was the number of death of patients who 
were hospitalized in the ICU of Kariadi hospital; 
while the independent variable was conjugated 
hyperbilirubinemia level. However, we did not 
investigate the confounding variables. 
The study population was patients who were 
hospitalized in the ICU. The inclusion criteria were 
patients who were treated in the ICU, patients with 
total bilirubin levels ≥ 1.3 mg/dL on day 3 or more 
following the intensive treatment, patients who had 
given informed consent, including the consent from 
their family.  The exclusion criteria were patients who 
had history of liver disease characterized by history or 
signs of chronic liver disease; patients with positive 
viral seromarker, blunt trauma, and extrahepatic 
obstruction; patients who died or discharged from the 
ICU < 48 hours after treatment.
 Each patient in the ICU who had hyperbilirubinemia 
was compared to another patient who did not 
have hyperbilirubinemia. They were interviewed 
to confirm the study outcome. The collected data 
was tested and the results showed no significant 
difference between the hyperbilirubinemia group and 
non-hyperbilirubinemia group. Continuous data which 
was normally distributed was tested by using the 
student t-test; while data with abnormal distribution 
was tested by using Mann Whitney test. Categorical 
or nominal variables were tested by Chi-square test or 
Fisher test. Univariate analysis of the study outcome 
was applied for variables that did not show any 
significant difference; while analysis of stratification 
for relative risk assessment was performed if there 
was significant difference between both groups The 
proportion of significance level of the variables 
was tested by calculating relative risk (RR) and was 
expressed as the level of significance α = 0.05 and 95% 
confidence interval (CI). The statistical analysis was 
performed by using SPSS version 15.
RESULTS
The study was conducted between May1st 2008 to 
January 31st 2009. Of the 552 patients treated in the 
ICU, 478 patients did not meet the inclusion criteria. 
Patients who fulfilled the criteria were included as the 
study patients and were categorized into two cohort 
groups, i.e. 31 patients in hyperbilirubinemia group 
and 48 patients in the non-hyperbilirubinemia group. 
Table 1. Characteristic of the patients with different test
Variable Hyperbilirubinemia Non hyperbilirubinemia p
Age > 60 years 9 (32.1%) 14 ( 50.0%) 0.174®
Acute respiratory distress syndrome 3 (10.7%) 7 (25.0%) 0.592@
Febris 6 (21.4%) 5 (17.8%) 0.787®
Heart failure 18 (64.3%) 12 (42.8%) 0.108®
Surgery patient 7 (25%) 5 (17.8%) 0.515®
Severe sepsis 14 (50%) 13 (46.4%) 0.174®
Ventilator positive end-expiratory 
      pressure > 12 cm H2O
3 (10.7%) 2 (7.1%) 0.639@
Hyperglicemia/hypoglicemia 4 (14.3%) 10 (35.7%) 0.121®
Thrombocyte abnormality 13 (46.4%) 11 (39.3%) 0.415®
Sodium level abnormality 15 (53.6%) 9 (32.1%) 0.105®
Ureum 88.7 ± 58.9 106.4 ± 111.6 0.926©
Potassium 4.3 ± 0.8 4.7 ± 1.5 0.21©
Heart rate 112.9 ± 17.1 113.3 ± 25.6 0.878©
Pulse 104.1 ± 16.1 105.7 ± 17.7 0.724o
Systolic blood pressure 122.4 ± 27.8 120.2 ± 38.9 0.807o
Diastolic blood pressure 72.5 ± 18.9 69.3 ± 22.4 0.556o
Hemoglobin 11.6 ± 2.5 10.9 ± 2.7 0.352o
Hematocryte 35.9 ± 8.3 33.1 ± 8.2 0.209o
Note: ®: X2 , @: Fisher’s exact test, ©: Mann Whitney, o: t-test
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy110
Agung Prasetyo, Djallalluddin, Hirlan, Agus Suryanto
The study found that the incidence of liver dysfunction 
in the ICU at Kariadi hospital was 39.2%. Among them, 
there were 28 patients with hyperbilirubinemia and 28 
patients who were non-hyperbilirubinemia. The mean 
age was 42 years; with the lowest age of 14 years and 
the highest age was 80 years. In average, the patients 
were at 40-66 years of age; while the median age was 
55 years. At the end of the study, the mortality rate in 
hyperbilirubinemia patients were 60.7% and 21.3% in 
the non-hyperbilirubinemia patients. The relative risk 
(RR) of death was 2.8; (95% CI = 1.3 - 6.1; p = 0.003).
It may occur because we included various risk factors 
in this study.
The correlation between hyperbilirubinemia 
and mortality at the ICU can be seen on figure 3. 
It shows that there were 17 (60.7%) patients who had 
hyperbilirubinemia and experienced the outcome of 
death; while there were only 11 (39.3%) patients who 
had the outcome death in non-hyperbilirubinemia 
group. Thus, the case fatality rate in critically-ill 
patients who were hospitalized in intensive care with 
liver dysfunction was 60.7%. The study indicates 
that the relative risk of death in patients with 
hyperbilirubinemia was 2.8 times (CI 95% = 1.3; RR 
< 6.1; p = 0.003). Such result suggests that the existence 
of hyperbilirubinemia in patients, who were treated in 
the ICU, will increase the risk of death by 2.8 times. 
Therefore, hyperbilirubinemia seems to have influence 
on the prognosis of patients hospitalized in the ICU. 
These results are consistent with the study results 
conducted by  Stravitz et al who reported that the death 
reached 50% in patients with acute liver failure who 
were treated in intensive care unit.8
Acute jaundice may also act as a marker of sepsis, 
multisystem organ failure (MSOF), or may reflect 
transient hypotension (shock-liver), right-sided heart 
failure, the metabolic breakdown of red blood cells, 
or pharmacologic toxicity. Such condition should 
lead us to suspected liver dysfunction and he patients 
may experience shock or sepsis, which increases 
the risk of death. Death caused by liver dysfunction 
may occur through extensive necrosis, followed 
by encephalopathy. It may also occur through liver 
failure, encephalopathy, brain edema, coagulopathy, 
hypoglycemia, electrolyte disturbances, respiratory 
problems, renal failure and secondary infection. 
Bleeding and coagulopathy hemodynamic disturbances 
may result, which leads to death.9-15 
Our study result indicates that the incident of 
hyperbilirubinemia should be concerned and further 
studies should be carried out about liver dysfunction 
in critically-ill patients who were hospitalized in the 
ICU. The assessment of hyperbilirubinemia performed 
on day 3 after the sign of jaundice may become the 
weakness in our study. 
CONCLUSION
The incidence of hyperbilirubinemia is frequently 
high in critically-ill patients who were hospitalized in 
the ICU of Kariadi hospital. This study demonstrates 
that there was significant difference regarding the 
incidence of death between non hyperbilirubinemia and 
hyperbilirubinemia patients. The significant relative 
risk of death indicates that hyperbilirubinemia has 
important influence on the mortality of critically-ill 
patients hospitalized in the intensive care unit.
Figure 1. Characteristic of the patients by sex
Figure 2. Characteristic of the patients by age
Figure 3. Correlation between hyperbilirubinemia and mortality
DISCUSSION
Of patients who were treated at the ICU of Kariadi 
hospital, we found the incidence of liver dysfunction 
as many as 39.2%. Such result is greater than that the 
results obtained by Ebert (22%) and Grau et al (23%).6,7 
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